Moxidectin
As of the edition of 20 October 2026, Moxidectin is a small molecule: marketed, first approved in 2018 (US); US protection ends in 2032.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Small molecule
- First approved
- 13 June 2018 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Medicines Development For Global Health
- Registered trials
- 22, 1 stopped early
- Disease areas
- Infections; Skin and connective tissue; Eye; Digestive system
US protection
US protection ends in 2032.
The last listed US exclusivity ends in 2032. The application that gives this date is held by Medicines Development For Global Health.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 7 | 5 | 1 | 1 |
| Phase 3 | 8 | 7 | 1 | 0 |
| Phase 4 | 2 | 1 | 1 | 0 |
| All trials | 22 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Medicines Development For Global Health | Originator | 2018 to now |